IL6 and viral pneumonia: For patients with severe viral pneumonia and hyperinflammation, the living guideline of the World Health Organization (WHO) 2022 stratifies patients by the oxygen requirement for treatment with an IL-6 blocker (tocilizumab or sarilumab) plus systemic corticosteroids if the C-reactive protein (CRP) concentration is ≥ 75 mg/L or the PaO2/FiO2 is < 300 mmHg.